Please login to the form below

Not currently logged in
Email:
Password:

Suboxone

This page shows the latest Suboxone news and features for those working in and with pharma, biotech and healthcare.

Reckitt hammered by $1.4bn opioid settlement bill

Reckitt hammered by $1.4bn opioid settlement bill

The federal investigation centred on a former Reckitt pharmaceutical subsidiary – spun off in 2014 and renamed Indivior – and marketing practices it deployed for Suboxone between 2006 and 2015. ... Suboxone, which is based on the powerful opioid

Latest news

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories.

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    That would help counteract a major setback for the business in the US a few weeks back when it lost a patent infringement lawsuit involving its main product Suboxone (buprenorphine and ... RBP-6000 is a long-acting form of buprenorphine that can be

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    The UK-listed company - which was spun out of Reckitt Benckiser three years ago - generates the bulk of its revenues from Suboxone (buprenorphine and naloxone), an oral film product used for ... As it stands, those two companies remain blocked from

  • Reckitt to spin-off pharma unit as Indivior Reckitt to spin-off pharma unit as Indivior

    Demerged business will focus on opioid dependence product Suboxone.  . UK firm Reckitt Benckiser has confirmed detailed of its plans to demerge its pharmaceuticals business. . ... RBP generates nearly all its revenues from Suboxone (buprenorphine and

  • Reckitt Benckiser confirms pharma spin-off plans Reckitt Benckiser confirms pharma spin-off plans

    The pharma unit generates nearly all its revenues from Suboxone (buprenorphine and naloxone), used for the treatment of opioid dependence, and - while prescription volumes for the product grew in the US - ... RB Pharma is trying to expand its product

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    Its share price took a massive hit when it was indicted by the US Justice Department earlier this year over its Suboxone Film therapy for opioid and heroin addiction, but its ... Indivior discovered buprenorphine, sold it under the brand name Subutex to

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The US market for the treatment of opioid addiction is currently dominated by Indivor’s Suboxone, a film that is placed under the tongue once a day.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Indivior will not be without its challenges as sales of its off-patent opioid addiction treatment Suboxone continue to slump.

  • Pharma deals during July 2014 Pharma deals during July 2014

    However, with revenues falling by 8 per cent in H1 2014 as a result of US generic competition for Suboxone (the pharma unit's top selling drug), it remains to be

  • Pharma deals during May 2014 Pharma deals during May 2014

    considered. A capital markets solution is emerging as a strong option.” The difficulty is that Suboxone (for treatment of drug addiction) sales are being hit by generic competition.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics